NDA 216718 · Biogen US
Skyclarys
Omaveloxolone · Oral
NovelPriority reviewOrphanCDER novel approval, Feb 28, 2023: To treat Friedrich's ataxia
Last checked: Nov 19, 2026Latest source record: Apr 7, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
Feb 28, 2023
Approved uses
2
Original approval plus efficacy supplements
Registered trials
20
1 Phase 3, 3 recruiting
FAERS reports
1,818
762 serious, 94 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Apr 6, 2026.
SKYCLARYS is indicated for the treatment of Friedreich's ataxia in adults and adolescents aged 16 years and older. SKYCLARYS is indicated for the treatment of Friedreich's ataxia in adults and adolescents aged 16 years and older. ( 1 )
Mechanism: The precise mechanism by which omaveloxolone exerts its therapeutic effect in patients with Friedreich's ataxia is unknown. Omaveloxolone has been shown to activate the Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway in vitro and in vivo in animals and humans. The Nrf2 pathway is involved in the cellular response to oxidative stress.
Therapeutic areas: Neurology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 20, 2024 Supplement 8 · Efficacy OrphanLabelLetter
- Feb 28, 2023 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelLetterReview
1 products under this application
- SKYCLARYS · OMAVELOXOLONE 50MG · CAPSULE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Omaveloxolone" as an intervention, any sponsor and status, largest first.
- RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARDPivotal-lookingCompleted
BiogenBiogen (BIIB)
NCT02128113 · 307 participants · Start May 31, 2014 · Primary completion Feb 28, 2015
Drug: Vehicle Ophthalmic Solution; Omaveloxolone Ophthalmic Suspension 0.5% and 1 more · For: Corneal Endothelial Cell Loss; Ocular Pain; Ocular Inflammation and 1 more
Sites: Laguna Hills, California; Lancaster, California; Cape Coral, Florida · 15 sites in all
- A Study to Learn More About the Effects and Long-Term Safety of Omaveloxolone (BIIB141) in Children and Teens With Friedreich's AtaxiaPivotal-lookingActive, not recruiting
BiogenBiogen (BIIB)
NCT06953583 · 255 participants (planned) · Start Jun 9, 2025 · Primary completion Nov 16, 2027
Drug: Omaveloxolone; Placebo · For: Friedreich Ataxia
Sites: Los Angeles, California; Gainesville, Florida; Tampa, Florida · 34 sites in all
- RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSEPivotal-lookingCompleted
BiogenBiogen (BIIB)
NCT02142959 · 187 participants · Start Jun 30, 2014 · Primary completion Apr 30, 2015
Drug: Omaveloxolone Lotion 0.5%; Omaveloxolone Lotion 3% and 1 more · For: Breast Cancer
Sites: Mesa, Arizona; Phoenix, Arizona; Scottsdale, Arizona · 27 sites in all
- A Study to Learn About the Effects and Safety of RTA 408 (Omaveloxolone) in People Aged 16 to 40 With Friedreich's AtaxiaPivotal-lookingCompleted
BiogenBiogen (BIIB)
NCT02255435 · 172 participants · Start Jan 31, 2015 · Primary completion Oct 31, 2019
Drug: Omaveloxolone Capsules, 2.5 mg; Omaveloxolone Capsules, 5 mg and 8 more · For: Friedreich Ataxia
Sites: Los Angeles, California; Gainesville, Florida; Tampa, Florida · 11 sites in all
- RTA 408 Lotion in Healthy VolunteersPivotal-lookingCompleted
BiogenBiogen (BIIB)
NCT02029716 · 109 participants · Start Dec 31, 2013 · Primary completion Apr 1, 2014
Drug: RTA 408 Lotion 0.5%, 1%, 3%; Lotion vehicle/placebo · For: Healthy
Sites: Cincinnati, Ohio
- RTA 408 Ophthalmic Suspension for the Treatment of Ocular Inflammation and Pain Following Ocular SurgeryPivotal-lookingCompleted
BiogenBiogen (BIIB)
NCT02065375 · 109 participants · Start Feb 28, 2014 · Primary completion Sep 30, 2014
Drug: Omaveloxolone Ophthalmic Suspension 1.0%; Omaveloxolone Opthalmic Suspension 0.5% and 1 more · For: Inflammation and Pain Following Ocular Surgery
Sites: Garden Grove, California; Fort Myers, Florida; Kansas City, Missouri · 6 sites in all
BiogenBiogen (BIIB)
NCT07297199 · 70 participants · Start Dec 12, 2025 · Primary completion May 1, 2026
Drug: Omaveloxolone · For: Healthy Volunteer
Sites: Austin, Texas
BiogenBiogen (BIIB)
NCT04008186 · 61 participants · Start Jun 14, 2019 · Primary completion Aug 18, 2019
Drug: Omaveloxolone; Midazolam oral solution and 7 more · For: Healthy Adult Subjects
Sites: Dallas, Texas
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- fatigue162
- nausea134
- hepatic enzyme increased130
- product dose omission issue107
- headache105
- diarrhoea95
- blood cholesterol increased86
- muscle spasms78
- fall76
- atrial fibrillation69
- alanine aminotransferase increased68
- death63
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2023 | 171 |
| 2024 | 665 |
| 2025 | 568 |
| 2026 | 414 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Skyclarys (Omaveloxolone)
2024 spending
$101M
Beneficiaries
380
3,241 claims
Per beneficiary
$266,507
$355.92 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $44,995,927 |
| 2024 | $101,272,750 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Safety and Efficacy of Omaveloxolone in Friedreich Ataxia (MOXIe Study).
Lynch DR, Chin MP, Delatycki MB, et al. · Ann Neurol 2021 · Clinical Trial, Phase II, Multicenter Study
- Safety, pharmacodynamics, and potential benefit of omaveloxolone in Friedreich ataxia.
Lynch DR, Farmer J, Hauser L, et al. · Ann Clin Transl Neurol 2019 · Clinical Trial, Phase II, Randomized Controlled Trial
- Efficacy of Omaveloxolone in Friedreich's Ataxia: Delayed-Start Analysis of the MOXIe Extension.
Lynch DR, Chin MP, Boesch S, et al. · Mov Disord 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Safety and efficacy of omaveloxolone v/s placebo for the treatment of Friedreich's ataxia in patients aged more than 16 years: a systematic review.
Umrao A, Pahuja M, Chatterjee NS · Orphanet J Rare Dis 2024 · Systematic Review, Research Support, Non-U.S. Gov't
- Clinical Assessment of the Drug-Drug Interaction Potential of Omaveloxolone in Healthy Adult Participants.
Zahir H, Murai M, Wu L, et al. · J Clin Pharmacol 2025 · Clinical Trial, Phase I, Multicenter Study
- Relative Bioavailability of Omaveloxolone When Capsules Are Sprinkled Over and Mixed in Applesauce Compared With Administration as Intact Omaveloxolone Capsules: A Phase 1, Randomized, Open-Label, Single-Dose, Crossover Study in Healthy Adults.
Hynes SM, Goldsberry A, Henneghan PD, et al. · J Clin Pharmacol 2024 · Clinical Trial, Phase I, Randomized Controlled Trial
Sponsor: Biogen
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.